The recurrence of this TPM3-NTRK1 gene fusion as an oncogene in colon cancer has been more recently confirmed, along with evidence that it is associated with sensitivity to TrkA inhibition [44]. The gene discussed is NTRK1; the disease is malignant colon neoplasm.